Related Experiment Videos
Pneumococcal vaccine. Efficacy and associated cost savings
C B Gable1, S S Holzer, L Engelhart
1Medical Technologies Assessment Division, SysteMetrics/McGraw-Hill, Washington, DC 20008.
JAMA
|December 12, 1990
Summary
The pneumococcal pneumonia vaccine is highly effective, showing 69% overall efficacy and significant cost savings. It offers greater protection for women than men, demonstrating value across various risk groups.
Area of Science:
- Immunology
- Public Health
- Health Economics
Background:
- Pneumonia remains a significant public health concern, particularly among at-risk populations.
- Vaccination is a key strategy for preventing infectious diseases and reducing healthcare burdens.
Purpose of the Study:
- To evaluate the real-world efficacy and cost-effectiveness of the pneumococcal pneumonia vaccine.
- To assess vaccine performance across different demographic and risk groups.
Main Methods:
- Retrospective cohort study utilizing medical and pharmaceutical claims data.
- Analysis of pneumonia incidence and vaccine efficacy in vaccinated versus unvaccinated individuals.
- Risk stratification based on ICD-9-CM diagnostic codes.
Main Results:
- Overall vaccine efficacy was 69%, with significantly higher efficacy in women (86%) compared to men (33%).
- Efficacy varied by risk category (50-75%), influenced by sex, with immunocompromised and immunocompetent women showing high protection (83-88%).
- Vaccination resulted in projected cost savings of $141 per person.
Conclusions:
- The pneumococcal pneumonia vaccine is effective in preventing pneumonia across diverse populations, including those with prior pneumonia or at-risk individuals.
- The vaccine demonstrates substantial cost savings, making it a valuable public health intervention.
- Sex-specific efficacy highlights the need for tailored public health messaging and strategies.